Overview of Chemotherapy in Advanced Ovarian Cancer
Author Information
Author(s): C.J. Williams
Primary Institution: Royal South Hants Hospital
Conclusion
The overview suggests that while the addition of other drugs to cisplatin may improve long-term survival, the results need to be confirmed in larger trials.
Supporting Evidence
- The 5-year survival rate for advanced ovarian cancer is about 20%.
- Platinum-based therapies showed only a small survival benefit.
- Patients often prefer small chances of improved survival despite increased side effects.
Takeaway
Doctors are trying to find better treatments for women with advanced ovarian cancer, but many past studies haven't been big enough to give clear answers.
Methodology
The overview analyzed various trials comparing different chemotherapy regimens for advanced ovarian cancer.
Potential Biases
There is a risk of bias due to the small size of many trials and the selection of patients.
Limitations
The trials included only patients deemed suitable for clinical research, which may not represent the general population.
Participant Demographics
Patients with advanced ovarian carcinoma, specifically FIGO Stage III and IV.
Statistical Information
Statistical Significance
not statistically significant
Want to read the original?
Access the complete publication on the publisher's website